

**Drugs and Therapeutics (D & T) Committee  
Meeting Results  
July 15, 2021**

<b>Drug Name</b>	<b>Review Type</b>	<b>Committee Recommendation</b>	<b>Preferred Status – Final Determination</b>
Cabenuva	New Drug Initial Review	Preferred	Preferred
Blenrep	New Drug Initial Review	Preferred	Non-Preferred
Avyakit	New Drug Initial Review	Non-Preferred	Non-Preferred
Xcopri	New Drug Initial Review	Preferred	Preferred
Entresto	New Drug Appeal	Preferred	Preferred
Fasenra	New Drug Appeal	Preferred	Preferred with PA
Symtuza	New Drug Appeal	Preferred	Preferred

**GLP-1 Receptor Agonists  
Class Review Results**

Adlyxin	Non-Preferred
Bydureon	Non-Preferred
Byetta	Non-Preferred (6-month grandfather)
Ozempic	Non-Preferred
Rybelsus	Non-Preferred (Pending Clarification)
Trulicity	Preferred
Victoza	Preferred

**Glucagon Emergency Products  
Class Review Results**

Baqsimi	Preferred
Glucagon ER Kits	Non-Preferred
Gvoke	Preferred
Zegalogue	Preferred

**SGLT-2 Inhibitors  
Class Review Results**

Farxiga	Preferred
Invokana	Preferred
Jardiance	Preferred
Steglatro	Non-Preferred